Epidermal growth factor receptor as a biomarker for cervical cancer

Soonthornthum, Tanomsiri; Arias-Pulido, Hugo; Joste, Nancy E.; Lomo, Lesley; Muller, Carolyn Y.; Rutledge, Teresa; Verschraegen, Claire F.

doi:10.1093/annonc/mdq723

Cited by 95 publications

(72 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Epidermal Growth Factor and its receptors were amongst the first identified biomarkers of cervical cancer (Soonthornthum et al, 2011;Gadducci et al, 2013). EGF is a mitotic growth factor overexpressed alongwith IGF I and IGF II, which are also overexpressed in cervical cancer.…”

Section: Egfsmentioning

confidence: 99%

Role of Cytokines in Genesis, Progression and Prognosis of Cervical Cancer

Paradkar¹,

Joshi²,

Mertia³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cytokine research is currently at the forefront in cancer research. Deciphering the functions of these multiple small molecules, discovered within the cell and in intercellular spaces, with their abundance and pleotrophism, was initially a great challenge. Advances in analytical chemistry and molecular biology have made it possible to unravel the pathophysiological functions of these polypeptides/proteins which are called interleukins, chemokines, monokines, lymphokines and growth factors. With more than 5 million women contracting cervical cancer every year this cancer is a major cause of mortality and morbidity the world over, particularly in the developing countries. In more than 95% of cases it is associated with human papilloma virus (HPV) infection which is persistent, particularly in those with a defective immune system. Although preventable, the mere magnitude of prevalence of HPV in the world population makes it a dominating current health hazard. The discovery of cytokine dysregulation in cervical cancer has spurted investigation into the possibility of using them as biomarkers in the early diagnosis of cases at high risk of developing cancer. Their critical role in carcinogenesis and progression of cervical cancer is now being revealed to a great extent. From diagnostics to prognosis, and now with a possible role in therapeutics and prevention of cervical cancer, the cytokines are being evaluated in all anticancer approaches. This review endeavours to capture the essence of the astonishing journey of cytokine research in cervical neoplasia.

show abstract

Section: Egfsmentioning

confidence: 99%

Role of Cytokines in Genesis, Progression and Prognosis of Cervical Cancer

Paradkar¹,

Joshi²,

Mertia³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Early stages are often treated surgically, but cervical cancer with distant metastases or recurrence remains uniformly fatal. 8 There are several approaches for cancer treatment, including surgery, radiation therapy, hormonal therapy, chemotherapy (either alone or in combination), and targeted therapy. Surgery is the primary treatment for early stage cervical cancer.…”

Section: Introductionmentioning

confidence: 99%

Combination of graphene oxide–silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells

Yuan¹,

Gurunathan²

2017

IJN

116

View full text Add to dashboard Cite

Background Cisplatin (Cis) is a widely used chemotherapeutic drug for treating a variety of cancers, due to its ability to induce cell death in cancer cells significantly. Recently, graphene and its modified nanocomposites have gained much interest in cancer therapy, due to their unique physicochemical properties. The objective of this study was to investigate the combination effect of Cis and a reduced graphene oxide–silver nanoparticle nanocomposite (rGO-AgNPs) in human cervical cancer (HeLa) cells. Materials and methods We synthesized AgNPs, rGO, and rGO-AgNP nanocomposites using C-phycocyanin. The synthesized nanomaterials were characterized using various analytical techniques. The anticancer properties of the Cis, rGO-AgNPs, and combination of Cis and rGO-AgNPs were evaluated using a series of cellular assays, such as cell viability, cell proliferation, LDH leakage, reactive oxygen species generation, and cellular levels of oxidative and antioxidative stress markers such as malondialdehyde, glutathione, SOD, and CAT. The expression of proapoptotic, antiapoptotic, and autophagy genes were measured using real-time reverse-transcription polymerase chain reaction. Results The synthesized AgNPs were well dispersed, homogeneous, and spherical, with an average size of 10 nm and uniformly distributed on graphene sheets. Cis, GO, rGO, AgNPs, and rGO-AgNPs inhibited cell viability in a dose-dependent manner. The combination of Cis and rGO-AgNPs showed significant effects on cell proliferation, cytotoxicity, and apoptosis. The combination of Cis and rGO-AgNPs had more pronounced effects on the expression of apoptotic and autophagy genes, and also significantly induced the accumulation of autophagosomes and autophagolysosomes, which was associated with the generation of reactive oxygen species. Conclusion Our findings substantiated rGO-AgNPs strongly potentiating Cis-induced cytotoxicity, apoptosis, and autophagy in HeLa cells, and hence rGO-AgNPs could be potentially applied to cervical cancer treatment as a powerful synergistic agent with Cis or any other chemotherapeutic agents.

show abstract

“…12 Despite the exact biological meaning of overexpression of EGFR receptor in cervical cancer is not clearly understood, a number of clinical studies have evaluated its blocking with either inhibitors of the EGFR tyrosine kinase or anti-EGFR monoclonal antibodies. 13 Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that competitively binds to the receptor preventing further ligand binding and EGFR activation.…”

Section: Introductionmentioning

confidence: 99%

A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer

Cetina¹,

Crombet

Jiménez-Lima

et al. 2015

Cancer Biology & Therapy

View full text Add to dashboard Cite

Nimotuzumab is a humanized IgG1 monoclonal antibody against the EGFR extracellular domain that has been evaluated in solid tumors as a single agent or in combination with chemotherapy and radiation. Cervical cancer patients who are refractory or progressive to first-line chemotherapy have a dismal prognosis, and no second-or thirdline chemotherapy is considered standard. This pilot trial aimed to evaluate the efficacy and safety of nimotuzumab in 17 patients with pre-treated advanced refractory or progressive cervical cancer. Nimotuzumab was administered weekly at 200 mg/m 2 as single agent for 4 weeks (induction phase), then concurrent with 6 21-day cycles of gemcitabine (800 mg/m 2 ) or cisplatin (50 mg/m 2 ) for 18 weeks (concurrent phase) and then once every 2 weeks (maintenance phase). Nimotuzumab could be continued beyond disease progression. Seventeen patients were accrued and evaluated for safety and efficacy. The median number of nimotuzumab applications was 20 (5-96). The median number of chemotherapy cycles administered was 6 (1-6). No toxicity occurred during induction and maintenance phases (single agent nimotuzumab). In the concurrent phase, grade 3 toxicity events observed were leucopenia, anemia and diarrhea in 11.7%, 5.8% and 11.7% respectively. No complete or partial responses were observed. The stable disease (SD) rate was 35%. The median PFS and OS rates were163 days (95% CI, 104 to 222), and 299 days (95% IC, 177 to 421) respectively. Nimotuzumab is well tolerated and may have a role in the treatment of advanced cervical cancer.

show abstract

Epidermal growth factor receptor as a biomarker for cervical cancer

Cited by 95 publications

References 83 publications

Role of Cytokines in Genesis, Progression and Prognosis of Cervical Cancer

Role of Cytokines in Genesis, Progression and Prognosis of Cervical Cancer

Combination of graphene oxide–silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells

A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer

Contact Info

Product

Resources

About

Epidermal growth factor receptor as a biomarker for cervical cancer

Cited by 95 publications

References 83 publications

Role of Cytokines in Genesis, Progression and Prognosis of Cervical Cancer

Role of Cytokines in Genesis, Progression and Prognosis of Cervical Cancer

Combination of graphene oxide&ndash;silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells

A pilot study of nimotuzumab plus single agent chemotherapy as second- or third-line treatment or more in patients with recurrent, persistent or metastatic cervical cancer

Contact Info

Product

Resources

About

Combination of graphene oxide–silver nanoparticle nanocomposites and cisplatin enhances apoptosis and autophagy in human cervical cancer cells